Search Results 71-80 of 9758 for Primary biliary cholangitis
Study To Evaluate The Safety, Tolerability, PDs, And Efficacy Of CNP-104 In Subjects With Primary Biliary Cholangitis · Share · Facebook · Twitter.
Primary sclerosing cholangitis is a chronic inflammation of the bile ducts of unknown cause and eventually results in cirrhosis of the liver. These patients are ...
About this study. The purpose of this study is to evaluate the safety and effectiveness of seladelpar in subjects with primary biliary cholangitis (PBC) and ...
About this study. Primary Biliary Cirrhosis (PBC) is a serious, life--threatening, bile acid related liver disease of unknown cause.
The purpose of this study is to assess the safety, tolerability and effectiveness of LJN452 for the treatment of patients who have primary biliary cholangitis.
Most people diagnosed with primary biliary cirrhosis, or PBC, in its early stages do not have any symptoms. Many remain symptom-free for years. Medication is ...
Primary biliary cholangitis and primary sclerosing cholangitis therapy landscape. American Journal of Gastroenterology. 2025; doi:10.14309/ajg ...
... primary biliary cholangitis (PBC). Participants will be treated with either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or ...
... PBC, and GLOBE) in Primary Biliary Cholangitis ... biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid.
... primary biliary cholangitis (PBC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.